Researchers study 'ACT TIL' approach to treating metastatic melanoma

October 17, 2012

Researchers at Moffitt Cancer Center have carried out a clinical trial in which patients with metastatic melanoma were given chemotherapy and an immunotherapy of adoptive cell transfer (ACT) with tumor infiltrating lymphocytes (TIL). Tumor tissues were surgically removed from patients, minced and grown in culture. The treatment combined chemotherapy, then ACT with TIL, followed by interleukin-2 (IL-2). The combination therapy drew a high response rate from some patients.

The study appears in the October issue of the Journal of .

"Our purpose was to demonstrate the feasibility of performing TIL growth and the efficacy of ACT TIL therapy using techniques developed at the ," said Amod Sarnaik, M.D., assistant member of the Cutaneous Oncology Department at Moffitt. "Combining chemotherapy with ACT and high dose IL-2 resulted in a 38 percent objective response rate in patients with metastatic melanoma."

"Although our clinical study successfully met its goal of demonstrating that ACT TIL therapy could be offered to advanced melanoma patients, strategies to improve on its feasibility and efficacy are under way," said Shari A. Pilon-Thomas, Ph.D., assistant member of the Immunology Program at Moffitt. "Combination therapies that enhance the proliferation and function of TIL are being explored."

Explore further: Tumor-Infiltrating lymphocyte grade IDs melanoma survival

More information: journals.lww.com/immunotherapy … l_Transfer_of.4.aspx

A second-generation ACT TIL trial is enrolling patients at Moffitt. For more, patients can go to the trial website or call Moffitt at 813-745-4279.

Related Stories

Tumor-Infiltrating lymphocyte grade IDs melanoma survival

June 20, 2012
(HealthDay) -- Tumor-infiltrating lymphocyte (TIL) grade is an independent predictor of melanoma-specific survival and sentinel lymph node (SLN) status in patients with localized primary cutaneous melanoma, according to a ...

Combination therapy delivers one-two punch to skin cancer, boosting anti-tumor activity

August 16, 2012
(Medical Xpress) -- Treating metastatic melanoma by combining immunotherapy with a drug that inhibits the cancer-spreading activity of a common gene mutation significantly increased survival times in an animal model, according ...

Researchers study effect of chemotherapy combined with immunotherapy for advanced cancers

October 9, 2012
Researchers at Moffitt Cancer Center and colleagues at the University of South Florida and Tianjin Medical University Cancer Institute and Hospital in China have discovered that combining chemotherapy drugs and immunotherapy ...

Response rate high for some patients with metastatic melanoma treated with vemurafenib

March 16, 2012
An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase ...

Immunotherapy and chemotherapy regimen may prolong survival in advanced cancers

April 3, 2012
Maintenance therapy with interleukin-2 and 13-cis retinoic acid may be an inexpensive method for increasing survival in patients with a variety of stage 4 cancers, according to data reported at the AACR Annual Meeting 2012, ...

Recommended for you

Exposure to larger air particles linked to increased risk of asthma in children

December 15, 2017
Researchers at The Johns Hopkins University report statistical evidence that children exposed to airborne coarse particulate matter—a mix of dust, sand and non-exhaust tailpipe emissions, such as tire rubber—are more ...

Bioengineers imagine the future of vaccines and immunotherapy

December 14, 2017
In the not-too-distant future, nanoparticles delivered to a cancer patient's immune cells might teach the cells to destroy tumors. A flu vaccine might look and feel like applying a small, round Band-Aid to your skin.

Immune cells turn back time to achieve memory

December 13, 2017
Memory T cells earn their name by embodying the memory of the immune system - they help the body remember what infections or vaccines someone has been exposed to. But to become memory T cells, the cells go backwards in time, ...

Steroid study sheds light on long term side effects of medicines

December 13, 2017
Fresh insights into key hormones found in commonly prescribed medicines have been discovered, providing further understanding of the medicines' side effects.

The immune cells that help tumors instead of destroying them

December 12, 2017
Lung cancer is the leading cause of cancer-associated deaths. One of the most promising ways to treat it is by immunotherapy, a strategy that turns the patient's immune system against the tumor. In the past twenty years, ...

Cancer gene plays key role in cystic fibrosis lung infections

December 12, 2017
PTEN is best known as a tumor suppressor, a type of protein that protects cells from growing uncontrollably and becoming cancerous. But according to a new study from Columbia University Medical Center (CUMC), PTEN has a second, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.